<DOC>
	<DOCNO>NCT02566993</DOCNO>
	<brief_summary>Phase III randomize clinical trial lurbinectedin ( PM01183 ) /doxorubicin ( DOX ) versus cyclophosphamide ( CTX ) , doxorubicin ( DOX ) vincristine ( VCR ) ( CAV ) topotecan treatment patient small-cell lung cancer ( SCLC ) fail one prior platinum-containing line determine difference progression-free survival ( PFS ) Independent Review Committee ( IRC ) lurbinectedin ( PM01183 ) /doxorubicin ( DOX ) control arm ( CAV ) topotecan analyze median overall survival ( OS ) mid- long-term overall survival ( OS 12 , 18 24 month ) .</brief_summary>
	<brief_title>Clinical Trial Lurbinectedin ( PM01183 ) /Doxorubicin ( DOX ) Versus Cyclophosphamide ( CTX ) , Doxorubicin ( DOX ) Vincristine ( VCR ) ( CAV ) Topotecan Treatment Patients With Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Voluntary write informed consent 2 . Adult patient ≥ 18 year 3 . Histologically cytologically confirm diagnosis limit extensive stage SCLC fail one prior platinumcontaining regimen chemotherapyfree interval ( CTFI , time last dose firstline chemotherapy occurrence progressive disease ) ≥ 30 day . Smallcell carcinoma unknown primary site without neuroendocrine feature confirm histology test ( ) perform metastatic lesion ( ) eligible , Ki67/MIB1 express &gt; 50 % tumor cell . 4 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) ≤ 2 . 5 . Adequate hematological , renal , metabolic hepatic function within 710 day prior randomization 6 . At least three week since last prior anticancer treatment adequate recovery prior treatment toxicity 7 . Prior radiotherapy ( RT ) : At least four week since completion wholebrain irradiation , least two week since completion prophylactic cranial irradiation , site . 8 . Evidence nonchildbearing status woman childbearing potential ( WOCBP ) . WOCBP must agree use highly effective contraceptive measure six week treatment discontinuation . Fertile male patient WOCBP partner use condom treatment four month follow last investigational medicinal product dose . 1 . More one prior chemotherapycontaining line ( rechallenge initial regimen allow ) 2 . Patients never receive platinumcontaining regimen Smallcell Lung Cancer ( SCLC ) 3 . Prior treatment PM01183 , topotecan anthracyclines . 4 . Limitedstage patient candidate local regional therapy 5 . Impending need palliative RT surgery pathological fracture and/or medullary compression within four week prior randomization . 6 . Symptomatic progressing steroid require Central Nervous System ( CNS ) involvement disease least four week prior randomization 7 . Concomitant diseases/conditions : Angina , myocardial infarction , congestive heart failure clinically significant valvular heart disease , arrhythmia , immunodeficiency ( include know HIV seropositive ) , ongoing treatmentrequiring chronic liver disease , active infection , oxygen requirement within two week prior randomization , diffuse interstitial lung disease ( ILD ) pulmonary fibrosis , second invasive malignancy treat chemotherapy and/or radiotherapy , invasive fungal infection require systemic treatment within 12 week randomization . 8 . Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>